However, combined blockade with anti-PD-1 and anti-CTLA-4 may potentiate Th1 cells, which are characterized by their production of IFN-γ and have been associated with a better prognosis in melanoma patients [41,49]. This evidence concerns the gene CTLA4 and melanoma.